SF 86-327 is a new allylamine class antifungal agent developed for both topical and oral administration by Sandoz Forschungsinstitut, Vienna, Austria (3; A. Stutz and G. Petranyi, Proc. 13th Int. Congr. Chemother., p. 116/1-116 /4, 1983) . This drug was designed to have maximal activity in vitro against dermatophytes and was found to inhibit many of these fungal species at as little as 0.003 mg/ml (G. Petranyi, J. G. Meingassner, and H. Mieth, Proc. 13th Int. Congr. Chemother., p. 116/9-116/12, 1983). This drug was also active in vitro against some other molds, such as Aspergillus species and Sporothrix schenckii (4; Petranyi et al., 13th ICC). However, its activity against yeasts has been substantially lower (Petranyi et until assayed. To assess the stability of the drug in storage, four serum samples with concentrations greater than 1 ,ug/ml were tested 50 days apart. Although an average decrease in concentration of 14% was found, this was considered to be within the error of the method.
Known drug standards or clinical serum samples (20 ,ul) were placed in wells (4 mm in diameter) which were at least 25 mm apart. All assays were performed in duplicate. Diameters of growth inhibition zones were measured after 24 h of incubation at 30°C. A linear relationship between log (2), sera from 8 and 10 h postdose were also obtained.
To assess the variability inherent in the bioassay, SF 86-327 was added to normal human serum at concentrations of 0.3, 1.0, and 3.0 ,ug/ml. The bioassay was done in duplicate in 16 separate runs on four different days, each of the 16 runs having its own standard curve. The within-run and between-run coefficients of variation (1) were 45 and 59% for 0.3 jig/ml, 16 and 17% for 1.0 ,ug/ml, and 1.9 and 14% for 3.0 ,ug/ml, respectively.
The results of 117 serum samples from the 5 patients are summarized in Table 1 . After the initial dose in three patients, the mean peak drug concentration was 1.27 + 0.25 (standard error of the mean) ,ug/ml, and the mean AUC was 4.06 + 1.62 ,ug * h/ml. At presumed steady state (5 to 436 days after the initiation of therapy), the mean peak SF 86-327 concentration in serum was 3.62 + 0.42 ,ug/ml, and the mean We thank Margret A. Huber for her technical assistance in performing the assays and Marilyn Malone for her preparation of special diets for our patients.
